Cerebral Amyloid Angiopathy
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Cerebral Amyloid Angiopathy is an early-stage landscape with 10 programs across 8 companies. The most active players are Roche, Alnylam Pharmaceuticals, Pfizer. 1 therapy is approved with 2 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
90%
Small molecule
9 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 83% of 12 pipeline programs.
Analysis
Trial Status
7
clinical trials
Clinical Trials
Trial Activity
7 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)